# Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

> **NCT00811967** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** PegIntron (peginterferon alfa-2b; SCH 54031)
- **DRUG:** Rebetol (ribavirin; SCH 18908)

## Key facts

- **NCT ID:** NCT00811967
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811967, "Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00811967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*